StockWatch
·
Q1 FY-2027 RESULTS · ZYDUSWELL

Zydus Wellness Q1 FY27: PAT down 7% YoY to ₹119 Cr as CCL costs squeeze margins

PAT -7.04% YoY · revenue +66.92% · margins compressing

Q1 FY27 resultsZYDUSWELLZYDUS WELLNESS LTD.-$04 Aug 2026 · 3 min read
Revenue

₹1,437 Cr

+66.92% YoY

PAT (consolidated)

₹118.9 Cr

-7.04% YoY

Net margin

8.25%

-6.6pp YoY

EPS

₹3.74

On a consolidated basis (primary), Zydus Wellness reported revenue of ₹1,437.0 Cr, up 66.9% YoY but down 3.2% QoQ, while PAT fell 7.0% YoY to ₹118.9 Cr and 26.6% QoQ from ₹162.0 Cr. The headline revenue jump is not organic growth — it reflects the full-quarter consolidation of Comfort Click Limited (CCL), acquired August 29, 2025, which the year-ago quarter did not carry at all. Notably, PBT actually rose 11.6% YoY to ₹162.1 Cr, so the entire PAT decline traces to items below the operating line.

The scoreboard

Q1 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹1,437 Cr-3.2%+66.9%
Expenses₹1,278.7 Cr-2.3%+77.9%
PAT₹118.9 Cr-26.6%-7.04%
Net margin8.25%-2.7pp-6.6pp
EPS₹3.74-26.5%-81.4%

NPM compressed to 8.3% from 14.8% YoY (10.9% QoQ) and OPM to 16.8% from 18.1% YoY (18.2% QoQ, using PBT-before-exceptionals less other income, plus finance cost and depreciation, over revenue — consistent with the margin convention in our records). The compression is driven by finance costs of ₹26.3 Cr (vs ₹2.5 Cr a year ago, a 10x jump) and depreciation/amortisation of ₹57.1 Cr (vs ₹10.8 Cr, ~5x) — both a direct consequence of CCL acquisition debt funding and PPA-related intangible amortisation. Separately, the effective tax rate rose sharply to 26.7% from 12.0% YoY, because a ₹4.6 Cr net MAT-credit-reversal benefit that lifted last year's quarter did not repeat this quarter (Note 6). Adjusting for that one-off tax item on a like-for-like basis, PAT would have been down only ~3.6% YoY rather than the reported 7.0% — meaning roughly half the headline PAT decline is a tax-benefit base effect, not a fresh operating deterioration, though margin compression from CCL financing/amortisation is real and structural for now.

466.48504.13541.78579.42617.07544.505-0405-2506-1707-1008-0308-04Q1 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹544.5, down 6.6% over the past month of trading.

₹ Cr
-79.7613.11105.99198.86171.9Q4 FY25rev ₹913 Cr127.9Q1 FY26rev ₹861 Cr-52.8Q2 FY26rev ₹651 Cr-39.9Q3 FY26rev ₹965 Cr162Q4 FY26rev ₹1,485 Cr118.9Q1 FY27rev ₹1,437 Cr
Quarterly consolidated PAT, ₹ Crore
Beyond the headline

What the summary numbers don't show

Consolidated EPS ₹3.74 for the quarter vs ₹5.09 in Q4FY26 and ₹4.02 in Q1FY26 (post-split-adjusted).

No exceptional items this quarter, versus ₹40.8 Cr of CCL-acquisition and NIPL-liquidation exceptional charges recorded across FY26.

What management guided (4 FY-2026 call)
Management expressed confidence in continued growth driven by innovation, portfolio scale-up, and margin expansion, leveraging data-driven and AI capabilities. While short-term headwinds for seasonal brands were noted due to weather, the company expects recovery. For the medium to long term, Zydus Wellness reiterates i

This quarter: missed

No formal analyst consensus for this specific quarter was found in a web search, so vs-street is unknown. On guidance: the FY26-Q4 call reiterated a medium-to-long-term aspiration of 17-18% EBITDA margin and flagged short-term weather-related headwinds for seasonal brands with an expected recovery — this quarter's 16.8% OPM remains below that band, and revenue was down sequentially rather than showing the flagged recovery, a miss against that qualitative bar. No press release/MD&A accompanied this filing (management framing not extracted), but the filing's own Note 4 states Group revenue and profit are seasonally skewed toward Q1 and Q4 — despite Q1 being a stated peak quarter, PAT still fell 26.6% QoQ, mostly via costs/tax rather than topline (revenue was down just 3.2% QoQ). The standalone (India) business, a cleaner read on the base business, grew steadily: revenue ₹153.0 Cr (+8.6% YoY) and PAT ₹5.5 Cr (+19.6% YoY). Among this quarter's other developments, the company incorporated a new UAE subsidiary (June 30, 2026), continuing its Middle East footprint alongside existing Zydus Wellness General Trading DWC-LLC and Zydus Wellness Trading LLC entities, and its Head of Sales resigned (July 3, 2026) — a governance item worth tracking but with no numbers attached yet; a Polish subsidiary was fined PLN 54,000 for a tax filing delay, an immaterial amount.

  • W1

    Whether finance costs and depreciation (₹26.3 Cr + ₹57.1 Cr this quarter, adding ~₹49 Cr of incremental cost YoY) moderate as CCL integration matures, given OPM of 16.8% still trails management's 17-18% EBITDA margin aspiration.

  • W2

    Whether Q2 revenue confirms the recovery from weather-related seasonal-brand headwinds management flagged on the May 2026 call, after this quarter's sequential revenue dipped 3.2% despite being a stated peak season.

  • W3

    Whether the MAT-credit-reversal tax benefit (absent this quarter, worth ₹4.6-21.8 Cr in the prior three quarters) recurs, which would materially aid reported PAT growth going forward.

Informational and educational content only. Not investment advice.